TOP2A TOP2A/90

CI-VAR-00004361Explore in graph →CIViC 3486

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Leukemia2
TOP2A TOP2A/90	Etoposide	Predictive	D	Supports Resistance	4	submitted	EID9634 In an in vitro study, leukemia cells expressing TOP2A/90 show increased inhibition (p < 0.025) upon KD of TOP2A/90 when treated with etoposide. Moreover cells expressing TOP2A/170 but not TOP2A/90 sho… (full text at CIViC) PMID 29514855 · Kanagasabai et al., 2018 · Open in CIViC	civic
TOP2A TOP2A/90	4'-(9-acridinylamino)methanesulfon-m-anisidide + DVP Regimen + Etoposide + MVT Regimen + PixantroneSubstitutes	Predictive	D	Supports Resistance	4	submitted	EID9635 In an in vitro study, leukemia cells expressing TOP2A/90 show increased IC50 compared to leukemia cells underexpressing TOP2A/90 when treated with etoposide, daunorubicin, mAMSA, mitoxantrone and pixa…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.